semaglutide patent expiration 2031 The Heavy Price of GLP-1 Drugs – I-MAK 2026-2031 | THE 5-YEAR PLAN

Obesity management for cardiovascular disease prevention

Its a notion that has been put to the test

Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively

Ships free, sealed, and temperature-monitored, with continuing access to your care team

It's impossible to know for sure without a medical evaluation